Investigating biomarkers for early prediction of bronchopulmonary dysplasia in preterm infants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify early biomarkers associated with bronchopulmonary dysplasia (BPD) in infants born at less than 30 weeks gestational age. Researchers will collect various samples, including breath, throat swabs, and placental samples, to analyze volatile organic compounds, airway mucins, and the microbiome. The study will monitor infants for the development of BPD, diagnosed at 36 weeks postmenstrual age based on respiratory support needs. Follow-up visits at 6 and 12 months will assess lung function and microbiome composition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Born at a gestational age \< 30 weeks

Exclusion Criteria:

* Major congenital defect or disorder
* Patients with an unstable general condition as deemed by the attending neonatologist

Where it's running

• University Hospital Antwerp
  Edegem, Antwerp, Belgium Recruiting

Study contacts

• Principal investigator: Antonius Mulder, MD, PhD,prof — University Hospital Antwerp, Belgium
• Study coordinator: Inès Ghys, MD
• Email: ines.ghys@uantwerpen.be
• Phone: +3232655230

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lung Ultrasound Score to predict BPD in very preterm babies

  This study tests whether lung ultrasound scores in the first two weeks of life can predict which extremely preterm babies will develop bronchopulmonary dysplasia.

  Recruiting at 4 sites Azienda USL Reggio Emilia - IRCCS · Modena and 3 other locations · NCT07633184

• Caffeine in pregnancy: how the mother and baby handle it during delivery

  This study tests how caffeine is processed in pregnant people and how much reaches the baby when given shortly before delivery.

  Recruiting Phase 1 Indiana University · Indianapolis, Indiana · NCT07570121

• IVIG for bronchopulmonary dysplasia in infants born at 28 weeks or earlier

  This trial will try intravenous immunoglobulin (IVIG) given over five days to see if it helps very preterm infants (≤28 weeks) who show early signs of bronchopulmonary dysplasia.

  Recruiting Phase 2 International Peace Maternity and Child Health Hospital · Shanghai · NCT07561125

• High-energy DHA/ARA-enriched human milk in the first 2 weeks to lower lung problems in extremely preterm babies

  This trial tests whether giving DHA/ARA-enriched, fortified human milk in the first 14 days after birth helps extremely preterm infants breathe easier and have better lung function.

  Recruiting Phase 1/2 University of Alabama at Birmingham · Birmingham, Alabama · NCT07307612

• Reduced versus higher daily fluids to prevent bronchopulmonary dysplasia in very preterm babies

  This tests whether giving smaller daily fluid volumes from day 8 of life (about 135 mL/kg/day) instead of larger volumes (about 165 mL/kg/day) lowers the chance of developing BPD or dying before 36 weeks in babies born before 30 weeks.

  Recruiting at 9 sites University Children's Hospital Basel · Aarau and 8 other locations · NCT06954142

• Using IVIG to treat bronchopulmonary dysplasia in premature infants

  This study is testing if a special immune treatment called IVIG can help premature babies with breathing problems caused by bronchopulmonary dysplasia feel better.

  Recruiting Phase 2 International Peace Maternity and Child Health Hospital · Shanghai, Shanghai Municipality · NCT06925360

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.